Abstract:High overexpression of sigma (σ) receptors (σ1 and σ2 subtypes) in a variety of human solid tumors has prompted the development of σ receptor-targeting radioligands, as imaging agents for tumor detection. A majority of these radioligands to date target the σ2 receptor, a potential marker of tumor proliferative status. The identification of approximately equal proportions of both σ receptor subtypes in prostate tumors suggests that a high affinity, dual σ receptor-targeting radioligand could potentially provide enhanced tumor targeting efficacy in prostate cancer. To accomplish this goal, we designed a series of ligands which bind to both σ receptor subtypes with high affinity. Ligand 3a in this series, displaying optimal dual σ receptor subtype affinity (σ1, 6.3 nM; σ2, 10.2 nM) was radiolabeled with fluorine-18 (18F) to give [18F]3a and evaluated as a σ receptor-targeting radioligand in the mouse PC-3 prostate tumor model. Cellular assays with PC-3 cells demonstrated that a major proportion of [18F]3a was localized to cell surface σ receptors, while ∼10% of [18F]3a was internalized within cells after incubation for 3.5 h. Serial PET imaging in mice bearing PC-3 tumors revealed that uptake of [18F]3a was 1.6 ± 0.8, 4.4 ± 0.3, and 3.6 ± 0.6% ID/g (% injection dose per gram) in σ receptor-positive prostate tumors at 15 min, 1.5 h, and 3.5 h postinjection, respectively (n = 3) resulting in clear tumor visualization. Blocking studies conducted with haloperidol (a nonselective inhibitor for both σ receptor subtypes) confirmed that the uptake of [18F]3a was σ receptor-mediated. Histology analysis confirmed similar expression of σ1 and σ2 in PC-3 tumors which was significantly greater than its expression in normal organs/tissues such as liver, kidney, and muscle. Metabolite studies revealed that >50% of radioactivity in PC-3 tumors at 30 min postinjection represented intact [18F]3a. Prominent σ receptor-specific uptake of [18F]3a in prostate tumors and its subsequent clear visualization with PET imaging indicate potential utility for the diagnosis of prostate carcinoma.

Synthesis and Biological Evaluation of a Novel 99mtc Cyclopentadienyl Tricarbonyl Complex ([(Cp-R)99mtc(co)3]) for Sigma-2 Receptor Tumor Imaging

Preparation and Biological Evaluation of 99mtcn‐4‐(cyclohexylpiperazin‐1‐yl)‐dithioformate As a Potential Sigma Receptor Imaging Agent

Novel 99m Tc Labeled Σ Receptor Ligand As a Potential Tumor Imaging Agent

Tc-99m-Cyclopentadienyl Tricarbonyl Chelate-Labeled Compounds As Selective Sigma-2 Receptor Ligands For Tumor Imaging

Novel cyclopentadienyl tricarbonyl (99m)tc complexes containing 1-piperonylpiperazine moiety: potential imaging probes for sigma-1 receptors.

Development of a Highly Specific 18F-Labeled Benzimidazolonebased Sigma-2 Receptor Radioligand for Brain Tumor Imaging

Development of a Highly Specific 18 F-Labeled Radioligand for Imaging of the Sigma-2 Receptor in Brain Tumors

Synthesis and Biological Evaluation of 18F Labeled Fluoro-Oligo-ethoxylated 4-Benzylpiperazine Derivatives for Sigma-1 Receptor Imaging

Synthesis and evaluation of a (18) F-labeled 4-phenylpiperidine-4-carbonitrile radioligand for σ1 receptor imaging.

Novel 18F-Labeled Benzimidazolone-Based Radioligands As Highly Selective Sigma-2 Receptor Probes for Tumor Imaging

Synthesis and evaluation of a 18F-labeled spirocyclic piperidine derivative as promising σ1 receptor imaging agent.

Design and Investigation of a [18F]-Labeled Benzamide Derivative as a High Affinity Dual Sigma Receptor Subtype Radioligand for Prostate Tumor Imaging.

Novel Radioligands for Imaging Sigma-1 Receptor in Brain Using Positron Emission Tomography (PET)

Synthesis and biological evaluation of novel 99mTc‐oxo and 99mTc‐tricarbonyl complexes with C3′‐functionalized thymidine dithiocarbamate for tumor imaging

Synthesis and evaluation of novel 18F-labeled spirocyclic piperidine derivatives as σ1 receptor ligands for positron emission tomography imaging

Synthesis and biological evaluation of a radioiodinated spiropiperidine ligand as a potential σ1 receptor imaging agent

Design, Synthesis and in Vitro Biological Evaluation of Reference Compounds of ~(123)I and ~(99)tc~m Labeled Indole Radiotracers for Σ_2 Receptor Imaging

Design, development and bio-evaluation of a novel radio-ligand 99mTc-THQ-DTPA as a sigma 2 receptor specific breast tumor imaging agent

F-Labeled benzylpiperazine derivatives as highly selective ligands for imaging σ receptor with positron emission tomography.

SYNTHESIS AND RADIOLABELING OF ~(99m)Tc-NITRIDO COMPLEX WITH 4-[(2-METHOXYPHENYL)PIPERAZIN-1-YL]-DITHIOFORMATE AS A POTENTIAL 5-HT_(1A) RECEPTOR IMAGING AGENT

Radiosynthesis and evaluation of novel 99m Tc(CO) 3 -labelled thymidine dithiocarbamate derivatives for tumor imaging with SPECT